Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 7
Submit an article Journal homepage
6,275
Views
28
CrossRef citations to date
0
Altmetric
Original Research

An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors

Satyen Harish GohilDepartment of Academic Haematology, University College London Cancer Institute, London, UK
,
Solange Rosa Paredes-MoscossoDepartment of Academic Haematology, University College London Cancer Institute, London, UK
,
Micaela HarrasserDepartment of Academic Haematology, University College London Cancer Institute, London, UK;Katharine Dormandy Haemophilia and Thrombosis Centre, London, UKORCID Iconhttp://orcid.org/0000-0002-2220-4683
ORCID Icon,
Marzia VezzaliniDepartment of Pathology and Diagnostics, University of Verona Medical School, Verona, ItalyORCID Iconhttp://orcid.org/0000-0002-5476-0844
ORCID Icon,
Aldo ScarpaDepartment of Pathology and Diagnostics, University of Verona Medical School, Verona, Italy
,
Emma MorrisInstitute of Immunity and Transplantation, University College London, Royal Free Hospital, Pond Street, London, UK
,
Andrew M. DavidoffDepartment of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA
,
Claudio SorioDepartment of Pathology and Diagnostics, University of Verona Medical School, Verona, Italy
,
Amit Chunilal NathwaniDepartment of Academic Haematology, University College London Cancer Institute, London, UK;Katharine Dormandy Haemophilia and Thrombosis Centre, London, UK;National Health Service Blood and Transplant, Oak House, Reeds Crescent, Watford, Hertfordshire, UKCorrespondence[email protected]
&
Marco Della PerutaDepartment of Academic Haematology, University College London Cancer Institute, London, UK
 show all
Article: e1326437 | Received 31 Aug 2016, Accepted 29 Apr 2017, Published online: 11 Jul 2017

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Amin Kamrani, Amir Mehdizadeh, Majid Ahmadi, Leili Aghebati-Maleki & Mehdi Yousefi. (2019) Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. Expert Opinion on Therapeutic Targets 23:5, pages 447-456.
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now

Articles from other publishers (26)

Kyung-Jun Lee, Nam-Hyeok Kim, Hyeong Su Kim, Youngmi Kim, Jae-Jun Lee, Jung Han Kim, Hye-Yon Cho, Soo Young Jeong & Sung Taek Park. (2023) The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells. Medicina 59:5, pages 994.
Crossref
Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt & Mohammad Hojjat-Farsangi. (2023) A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells. Pharmaceutics 15:4, pages 1148.
Crossref
Daniel Andrés Osorio-Rodríguez, Bernardo Armando Camacho & César Ramírez-Segura. (2023) Anti-ROR1 CAR-T cells: Architecture and performance. Frontiers in Medicine 10.
Crossref
Soo Young Jeong, Kyung-jun Lee, Jieum Cha, So Yoon Park, Hyeong Su Kim, Jung Han Kim, Jae-Jun Lee, Namhyeok Kim & Sung Taek Park. (2022) Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1). Medicina 58:12, pages 1867.
Crossref
Micaela Harrasser, Satyen Harish Gohil, Hiu Lau, Marco Della Peruta, Vincent Muczynski, Dominic Patel, Elena Miranda, Kristiana Grigoriadis, Anita Grigoriadis, David Granger, Rachel Evans & Amit Chunilal Nathwani. (2022) Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC. Breast Cancer Research 24:1.
Crossref
Eileen Y. Hu, Priscilla DoSwagata Goswami, Jessica Nunes, Chi-ling Chiang, Sara Elgamal, Ann M. Ventura, Carolyn Cheney, Kevan Zapolnik, Erich Williams, Rajeswaran Mani, Frank Frissora, Xiaokui MoLorenz Waldmeier, Roger R. Beerli, Haiyong PengChristoph Rader, Meixiao Long, Ulf Grawunder, John C. Byrd & Natarajan Muthusamy. (2021) The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Advances 5:16, pages 3152-3162.
Crossref
Yuming Zhao, Dengyang Zhang, Yao Guo, Bo Lu, Zhizhuang Joe Zhao, Xiaojun Xu & Yun Chen. (2021) Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies. Frontiers in Oncology 11.
Crossref
Oladapo O. Yeku, Thapi Dharma Rao, Ian Laster, Artem Kononenko, Terence J. Purdon, Pei Wang, Ziyou Cui, Hong Liu, Renier J. Brentjens & David Spriggs. (2021) Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. Frontiers in Immunology 12.
Crossref
Kerstin Menck, Saskia Heinrichs, Cornelia Baden & Annalen Bleckmann. (2021) The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells 10:1, pages 142.
Crossref
Erin Morales, Michael Olson, Fiorella Iglesias, Saurabh Dahiya, Tim Luetkens & Djordje Atanackovic. (2020) Role of immunotherapy in Ewing sarcoma. Journal for ImmunoTherapy of Cancer 8:2, pages e000653.
Crossref
Masakazu Hamada & Yoshiaki Yura. (2020) Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer. International Journal of Molecular Sciences 21:19, pages 7073.
Crossref
Pablo Lopez-Bergami & Gastón Barbero. (2020) The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment. Cancer and Metastasis Reviews 39:3, pages 933-952.
Crossref
Amineh Ghaderi, Amir Hossein Daneshmanesh, Ali Moshfegh, Parviz Kokhaei, Jan Vågberg, Johan Schultz, Thomas Olin, Sara Harrysson, Karin E Smedby, Elias Drakos, Georgios Z. Rassidakis, Anders Österborg, Håkan Mellstedt & Mohammad Hojjat-Farsangi. (2020) ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. Biomedicines 8:6, pages 170.
Crossref
Marco Cerrano, Marco Ruella, Miguel-Angel Perales, Candida Vitale, Danilo Giuseppe Faraci, Luisa Giaccone, Marta Coscia, Molly Maloy, Miriam Sanchez-Escamilla, Hesham Elsabah, Afraa Fadul, Enrico Maffini, Gianfranco Pittari & Benedetto Bruno. (2020) The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Frontiers in Immunology 11.
Crossref
Rebecca C. Abbott, Ryan S. Cross & Misty R. Jenkins. (2020) Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. International Journal of Molecular Sciences 21:2, pages 515.
Crossref
Faizan Ahmad. (2020) Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies. Biomedical and Biotechnology Research Journal (BBRJ) 4:3, pages 179.
Crossref
Joseph Mikhael. (2020) Treatment Options for Triple-class Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 20:1, pages 1-7.
Crossref
Mark Agostino & Sebastian Öther-Gee Pohl. (2019) Wnt Binding Affinity Prediction for Putative Frizzled-Type Cysteine-Rich Domains. International Journal of Molecular Sciences 20:17, pages 4168.
Crossref
Mark B. Leick & Marcela V. Maus. (2019) CAR-T cells beyond CD19, UnCAR-Ted territory. American Journal of Hematology 94:S1, pages S34-S41.
Crossref
Satyen H. Gohil, Rachel Evans, Micaela Harasser, Mohamed El‐Kholy, Solange R. Paredes‐Moscosso, Marco Della Peruta & Amit C. Nathwani. (2019) Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia. British Journal of Haematology.
Crossref
Michelle H. Townsend, Gajendra Shrestha, Richard A. Robison & Kim L. O’Neill. (2018) The expansion of targetable biomarkers for CAR T cell therapy. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Jian Li, Wenwen Li, Kejia Huang, Yang Zhang, Gary Kupfer & Qi Zhao. (2018) Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. Journal of Hematology & Oncology 11:1.
Crossref
Hanna Karvonen, Robert Perttilä, Wilhelmiina Niininen, Harlan Barker & Daniela Ungureanu. (2018) Targeting Wnt signaling pseudokinases in hematological cancers. European Journal of Haematology 101:4, pages 457-465.
Crossref
Junpeng QiXiuling LiHaiyong PengErika M. CookEman L. DadashianAdrian WiestnerHaJeung Park & Christoph Rader. (2018) Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. Proceedings of the National Academy of Sciences 115:24.
Crossref
Markus Kieler, Matthias Unseld, Daniela Bianconi & Gerald Prager. (2018) Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. Pancreas 47:2, pages 142-157.
Crossref
Carol S. Leung. (2018) Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components. Journal of Immunology Research 2018, pages 1-10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.